Pfizer Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Portfolio Pulse from Avi Kapoor
Pfizer Inc. (NYSE:PFE) is set to release its Q2 financial results, with analysts expecting earnings of 46 cents per share and revenue of $13.02 billion. The company recently received European Commission approval for DURVEQTIX, a gene therapy for hemophilia B. Analysts have mixed ratings on the stock, with price targets ranging from $28 to $45.
July 30, 2024 | 5:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer is set to release its Q2 earnings, with expectations of 46 cents per share and $13.02 billion in revenue. The company also received EU approval for DURVEQTIX. Analysts have mixed ratings, with price targets ranging from $28 to $45.
The upcoming earnings report and recent EU approval for DURVEQTIX are significant events for Pfizer. The mixed analyst ratings suggest varied expectations, but the overall sentiment appears cautiously optimistic.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100